Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | RXRB | P28702 | 1/20 | 0.61 |
| ▸ | RXRG | P48443 | 1/20 | 0.61 |
| ▸ | XDH | P47989 | 2/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026568 | 0.87 | XDH (0.71) | MRGPRX4NR4A2XDHALDH1A1HPGD | |
| SCHEMBL20897512 | 0.87 | MRGPRX4 (0.63) | MRGPRX4NR4A2RXRARXRBRXRG | |
| SCHEMBL28583625 | 0.86 | XDH (0.80) | MRGPRX4XDH | |
| SCHEMBL6211864 | 0.84 | MRGPRX4 (0.62) | MRGPRX4ALDH1A1 | |
| SCHEMBL698500 | 0.83 | MRGPRX4 (0.80) | MRGPRX4NR4A2RXRARXRBRXRG | |
| SCHEMBL366522 | 0.82 | MRGPRX4 (0.56) | MRGPRX4MGLLALDH1A1 | |
| SCHEMBL21585885 | 0.82 | MAOB (0.65) | MRGPRX4NR4A2RXRARXRBRXRG | |
| SCHEMBL20898187 | 0.81 | MRGPRX4 (0.81) | MRGPRX4NR4A2RXRARXRBRXRG | |
| SCHEMBL28575362 | 0.80 | XDH (0.81) | XDH | |
| SCHEMBL20897436 | 0.78 | MRGPRX4 (0.82) | MRGPRX4NR4A2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3694840-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | Hoffmann-La Roche AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019072785-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | MRGPRX4 85/4885NR4A2 4745/4885RXRA 4515/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | MRGPRX4 85/4885NR4A2 4745/4885RXRA 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.